Autolus Therapeutics (AUTL) Cash & Equivalents (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Cash & Equivalents data on file, last reported at $104.1 million in Q4 2025.

• Quarterly Cash & Equivalents fell 54.2% year-over-year to $104.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $104.1 million (down 54.2% YoY) and the FY2025 annual result came in at $104.1 million, down 54.2% from the prior year.
• Cash & Equivalents grew to $104.1 million in Q4 2025, from $86.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $758.5 million in Q1 2024 to a low of $86.1 million in Q3 2025.
• A 5-year average of $293.7 million and a median of $239.3 million in 2021 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 156.25% — and 2025, when it plunged 87.37%.
• Tracing AUTL's Cash & Equivalents over 5 years: stood at $310.3 million in 2021, then grew by 23.23% to $382.4 million in 2022, then slumped by 37.36% to $239.6 million in 2023, then slipped by 5.09% to $227.4 million in 2024, then tumbled by 54.2% to $104.1 million in 2025.
• The last three Cash & Equivalents figures came in at $104.1 million (Q4 2025), $86.1 million (Q3 2025), and $123.8 million (Q2 2025), per Business Quant data.